Bloomberg Law
March 14, 2022, 5:30 PM

Mylan $264 Million EpiPen Price-Gouge Deal Gets First Court Nod

Mike Leonard
Mike Leonard
Legal Reporter

Consumers and insurers leading price-gouging litigation over the EpiPen, a treatment for life-threatening allergic reactions, won preliminary approval from a federal judge in Kansas for their $264 million settlement with affiliates of Mylan NV, which markets the device.

Judge Daniel D. Crabtree tentatively signed off March 11 on the deal, which would resolve class action antitrust claims brought against Mylan in the U.S. District Court for the District of Kansas of behalf of “end payers” like insurers, pension funds, and consumers. He set a final fairness hearing for July 6.

The agreement broadly resembles a $345 million pact with ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.